| Literature DB >> 25375833 |
Kenneth D'Souza1, Yeun Ju Kim, Tamas Balla, Richard M Epand.
Abstract
Entities:
Mesh:
Substances:
Year: 2014 PMID: 25375833 PMCID: PMC4255645 DOI: 10.1021/bi501250m
Source DB: PubMed Journal: Biochemistry ISSN: 0006-2960 Impact factor: 3.162
Lipids Used in This Study
| abbreviation | full name | |
|---|---|---|
| SAPA | 1-stearoyl-2-arachidonoyl- | 18:0/20:4 PA |
| PAPA | 1-palmitoyl-2-arachidonoyl- | 16:0/20:4 PA |
| DAPA | 1,2-diarachidonoyl- | 20:4/20:4 PA |
| SLPA | 1-stearoyl-2-linoleoyl- | 18:0/18:2 PA |
| SOPA | 1-stearoyl-2-oleoyl- | 18:0/18:1 PA |
| SDPA | 1-stearoyl-2-docosahexaenoyl- | 18:0/22:6 PA |
| DLPA | 1,2-dilinoleoyl- | 18:2/18:2 PA |
| DOPA | 1,2-dioleoyl- | 18:1/18:1 PA |
| SAPI | 1-stearoyl-2-arachidonoyl- | 18:0/20:4 PI |
| SLPI | 1-stearoyl-2-linoleoyl- | 18:0/18:2 PI |
| DLPI | 1,2-diolinoleoyl- | 18:2/18:2 PI |
| DLPG | 1,2-diolinoleoyl- | 18:2/18:2 PG |
Naturally Derived Phospholipid Species Used in This Studya
| abbreviation | full name | predominant acyl chain | ref |
|---|---|---|---|
| soy PI | soy | 18:2 (42%), 16:0 (37%) | ( |
| liver PI | liver | 18:0 (32%), 20:4 (23%) | ( |
| brain PIP | brain | 18:0 (33%), 20:4 (33%) | ( |
| brain PIP2 | brain | 18:0 (33%), 20:4 (33%) | ( |
| soy PG | soy | 18:2 (65%) | ( |
| egg PG | egg | 16:0 (39%), 18:1 (24%) | ( |
The predominant acyl chain compositions are listed.
Soy phosphatidylglycerol prepared by transphosphatidylation of soy phosphatidylcholine. Hence, the acyl chain composition of soy PG reflects that of soy PC.
Figure 1Comparison of enzymatic activity for CDS1 and CDS2. Mixed micelle-based enzymatic activity of CDS1 and CDS2 using SAPA and SLPA as substrates. (A) CDS1 and (B) CDS2 both exhibit surface dilution kinetics, with maximal activities seen at 5.1 mM Triton X-100. (C) Crude activity of COS7 lysates containing EV-, CDS1-, or CDS2-transfected cells with and without PA substrates. (D) Specific activity of CDS1 and CDS2. Enzymatic activity is adjusted using EV-myc and normalized using calnexin. The bars with asterisks were determined to be statistically different (P < 0.05). Data are represented as the mean ± SEM. (E) Immunoblots of lysates of COS7 cells overexpressing either CDS1 or CDS2 constructs carrying a myc tag. Detection of calnexin used as a control.
Figure 3Substrate specificity of CDS1 and CDS2. A mixed micelle assay was used to test enzymatic activity using a variety of substrates. PA concentrations were quantified prior to use, and 1 mol % substrates (50 μM) were used for each assay. The substrate specificity of CDS1 was measured by varying the (A) sn-1, (B) sn-2, and (C) sn-1/sn-2 acyl chains. The substrate specificity of CDS2 was measured by varying the (D) sn-1, (E) sn-2, and (F) sn-1/sn-2 acyl chains. The bars with asterisks were determined to be statistically different (P < 0.05). Data are represented as the mean ± SEM. The activities of CDS1 and CDS2 are 164.4 ± 4.6 and 289.8 ± 12.8 pmol of CDP-DG/min, respectively, and are defined as 100% for SAPA.
Figure 2Kinetics of CDS1 and CDS2. Mixed micelle-based enzymatic assays of CDS1 and CDS2 at various mole percents of SAPA and SLPA. Both (A) CDS1 and (B) CDS2 show typical saturation kinetics. (C) Mixed micelle-based enzymatic activity of CDS1 and CDS2 using SAPA and SLPA at a low level of 0.1 mol %. Enzymatic activity is adjusted using mock-transfected COS7 cells (EV control). The kinetic parameters are summarized in Table 3. Data are represented as the mean ± SEM.
Summary of Kinetic Parameters for CDS1 and CDS2a
| lipid species | |||||
|---|---|---|---|---|---|
| CDS1 | SAPA | 3.3 ± 0.3 | 0.8 ± 0.2 | 2.9 ± 0.3 | 3.6 ± 1.4 |
| SLPA | 3.6 ± 0.1 | 0.6 ± 0.1 | 3.2 ± 0.2 | 5.3 ± 1.0 | |
| CDS2 | SAPA | 9.3 ± 0.4 | 1.4 ± 0.2 | 8.0 ± 0.3 | 5.7 ± 1.0 |
| SLPA | 3.5 ± 0.1 | 0.9 ± 0.1 | 2.9 ± 0.1 | 3.2 ± 0.5 |
A mixed micelle assay was used to test enzymatic activity over a series of substrate concentrations. Substrate concentrations are represented as mole percent SAPA. The low enzymatic activity from EV-myc is subtracted, and the activity is then normalized using calnexin. Data are represented as the mean ± SEM. The kcat/Km of CDS2 for SAPA is significantly greater than that of SLPA, whereas the kcat/Km values of CDS1 for SAPA and SLPA are not.
Determined to be statistically different from the value for SAPA (P < 0.05).
Figure 4Activity and subcellular localization of labeled CDS1 and CDS2. (A) Mixed micelle activity assay used to determine the substrate specificity of CDS1-GFP and CDS2-GFP. (B) ER localization of CDS1 and CDS2 enzymes. Cells were transfected with the indicated constructs and immunostained as detailed in the Experimental Procedures. Note the color conversion in the top left and bottom two panels where the GFP is detected with a red secondary antibody (the GFP fluorescence is quenched by our fixation procedure that preserves the ER architecture). Both CDS forms are ER-localized with only subtle differences: CDS1 being more enriched in the central ER and CDS2 being slightly more prevalent in peripheral ER sheets. The activities of CDS1 and CDS2 are 156.9 ± 15.7 and 202.6 ± 4.2 pmol of CDP-DG/min, respectively, and are defined as 100% for SAPA.
Figure 5Inhibition of CDS1 and CDS2 by natural phospholipid species. A mixed micelle assay was used to determine the inhibition of CDS1 and CDS2 with naturally derived PI and PG species. An equal mole percent of phospholipids was used as the substrate PA, unless otherwise noted. The concentration of all lipid species was quantified prior to use. Black bars represent the presence of the substrate, SAPA, only. Other bars represent the same concentration of SAPA together with a second lipid of equimolar or 4-fold higher concentration, as indicated on the graph: (A) PI inhibition of CDS1, (B) PG inhibition of CDS1, (C) PI inhibition of CDS2, and (D) PG inhibition of CDS2. The bars with asterisks were determined to be statistically different (P < 0.05). Data are represented as the mean ± SEM. The activities of CDS1 and CDS2 are 176.9 ± 22.6 and 231.6 ± 6.7 pmol of CDP-DG/min, respectively, and are defined as 100% for SAPA.
Figure 6Inhibition of CDS1 and CDS2 by PI and PG species. A mixed micelle assay was used to determine the inhibition of CDS1 and CDS2 with select PI and PG species. The concentrations of all species were quantified prior to use. The activity as compared to EV controls: (A) CDS1 and (B) CDS2. The bars with asterisks were determined to be statistically different (P < 0.05). Data are represented as the mean ± SEM. The activities of CDS1 and CDS2 are 88.9 ± 3.7 and 160.4 ± 10.8 pmol of CDP-DG/min, respectively, and are defined as 100% for SAPA.